Pathological Micro-Niches and Multimodal Imaging Macro-Niches for Predicting Clinically Significant Prostate Cancer and Metastasis: A Multicenter Study
A legfontosabb adatok
- Ki végzi
- Guangxi Medical University
- Hol
- Kína1 helyszín, 1 országbanVálassz országot a helyszínekhez
- Azonosító
- Állapot
- Fut, nem toboroz
- Résztvevők
- 2000 fő, tervezett
- Kezdés
- 2014. jan.
- Várható befejezés
- 2029. okt.
- A vizsgálat típusa
- Megfigyeléses, 4 csoport
- A regiszteradat frissítve
- 2026. november 13.
Ki vehet részt
- Életkor
- 18 év felett
- Nem
- Csak férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 10 feltétel megnézéseKevesebb
Ki vehet részt
- Age 18 years or older
- Evaluated, diagnosed, or followed for suspected or confirmed prostate cancer at a participating center
- A unique patient-level study ID can be established and the temporal order of key examinations, pathology sampling, and treatment can be confirmed
- At least one qualified imaging, pathology, clinical, or follow-up dataset required by a substudy is available
- Data use conforms to ethical approval, informed consent, or the approved retrospective consent-waiver scope
Ki nem vehet részt
- Reliable de-duplication, or the before/after order of the prediction time point and endpoint, cannot be confirmed
- Core imaging, pathology, or outcome data are damaged and cannot pass quality control
- Required data use exceeds the original authorization and ethical approval has not been obtained
- Use is prohibited by laws or regulations, collaboration agreements, or an ethical decision
- For a specific substudy, the primary reference standard is missing or clear label leakage cannot be corrected
Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.
Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
This is an investigator-initiated, multicenter, observational ambispective cohort study, predominantly retrospective, with an optional prospective non-interventional silent validation. The study tests a cross-scale hypothesis that the pathological micro-niche of the primary prostate tumor (tumor epithelium, invasive front, immune-rich or immune-poor regions, ECM/collagen remodeling, neurovascular neighborhoods, and peritumoral field effect) is associated at the patient level with the imaging macro-niche captured by multiparametric MRI (diffusion, perfusion, heterogeneity, local invasion) and PSMA PET/CT (receptor expression, whole-body lesion distribution, tumor burden). A pathology teacher model provides patient- or lesion-set-level niche representations only during model development; at deployment and validation, only MRI, PSMA PET/CT, and clinical information available before the prediction time point are used, with no voxel-level pathology-to-imaging registration. Under one master protocol with three pre-specified substudies, the system predicts: (A) patient- and lesion-level clinically significant prostate cancer (csPCa, ISUP Grade Group 2 or higher) from pre-biopsy MRI; (B) pathological pelvic lymph node metastasis (pN1) after radical prostatectomy with pelvic lymph node dissection, primarily from MRI; and (C) concurrent distant metastasis (M1) and subsequent distant metastasis in baseline M0 patients, primarily from PSMA PET/CT. Models are evaluated for discrimination, calibration, clinical net benefit, uncertainty, abstention, and stability across centers, scanners, tracers, and disease spectra, using locked multicenter external validation and prospective silent validation. Model outputs are never shown to clinicians or patients and do not alter care.
A vizsgálat 4 csoportja
- Substudy A: csPCa Prediction Cohort
Patients who completed MRI before biopsy or surgery; patient- and lesion-level clinically significant prostate cancer (Grade Group 2 or higher) is predicted from MRI and pre-prediction clinical variables, with tiered pathology reference standards.
- Substudy B: pN1 Prediction Cohort
Patients undergoing radical prostatectomy combined with pelvic lymph node dissection; pathological pN1 is predicted preoperatively, primarily from MRI with PSMA PET/CT as an optional incremental input.
- Substudy C1: Concurrent M1 Prediction Cohort
Patients within the +/-90-day pre-treatment baseline staging window; concurrent distant metastasis (M1) is predicted primarily from PSMA PET/CT and confirmed by a blinded multidisciplinary composite reference.
- Substudy C2: Subsequent Metastasis Prediction Cohort
Patients confirmed M0 at baseline who are followed from a pre-specified landmark for the first distant metastasis, with treatment as time-dependent and death as a competing event.
Adatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- A Multicenter Study of Pathological Micro-Niches and Multimodal Imaging Macro-Niches for Predicting Clinically Significant Prostate Cancer and Metastasis: Patient-Level Cross-Scale Knowledge Transfer From Histology to MRI and PSMA PET/CT
- A regiszteradat frissítve
- 2026. november 13.